GlassScriptPhysician profile
Luke Richard Frederick
NPI 1043507866
$3,864.67
in general payments reported to CMS, 2019-2025
36 companies · $600 in 2025
The $600 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $216 · 2021: $295 · 2022: $752 · 2023: $690 · 2024: $881 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.51 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $480.56 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $336.51 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $318.98 | 2019-2024 | Provenge |
| Cook Medical LLC | $272.37 | 2019-2023 | Resonance |
| Abbvie INC. | $237.50 | 2019-2025 | |
| Boston Scientific Corporation | $234.50 | 2021-2025 | Ams 800 Artificial Urinary Sphincter, Lithovue |
| Janssen Biotech, INC. | $212.41 | 2019-2025 | Erleada, Akeega, Balversa |
| Teleflex LLC | $202.69 | 2021-2025 | Urolift, Barrigel |
| Verity Pharmaceuticals INC. | $162.27 | 2022-2024 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $161.34 | 2023-2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $144.21 | 2020-2024 | |
| Coloplast Corp | $124.49 | 2019-2024 | Speedicath |
| Myovant Sciences INC. | $119.22 | 2022 | |
| Olympus America INC. | $106.60 | 2022-2025 | Itind System |
| Travere Therapeutics, INC. | $102.75 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $66.87 | 2024-2025 | Xt Cdx |
| Rochester Medical Corporation | $61.21 | 2022 | |
| Pfizer INC. | $56.93 | 2025 | |
| Angiodynamics, INC. | $48.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.66 | 2024-2025 | |
| C. R. Bard, INC. & Subsidiaries | $46.96 | 2025 | Bard Urinary Drainage Bag |
| Tolmar, INC. | $39.97 | 2024 | |
| Bard Access Systems, INC. | $31.17 | 2019 | |
| 180 Medical, INC. | $29.47 | 2023 | Gentlecath |
| Medtronic, INC. | $25.15 | 2023 | Interstim |
| Convatec INC. | $23.26 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $22.40 | 2022 | |
| Merck Sharp & Dohme LLC | $20.39 | 2023 | Keytruda, Lynparza |
| Amgen INC. | $19.66 | 2019 | |
| Endo USA, INC. | $19.29 | 2024 | Xiaflex |
| Accord Healthcare, INC. | $19.17 | 2025 | |
| Koelis INC. | $16.14 | 2023 | |
| Urogen Pharma, INC. | $14.29 | 2023 | Jelmyto |
| Sun Pharmaceutical Industries INC. | $13.61 | 2023 | Yonsa |
| Cardinal Health 414 LLC | $13.47 | 2023 | |
| Neotract INC. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.